So the key catalyst will be the P3 OA top line readout, potentially around October 2024, and only if the FDA allow us to up the dose to 2mg/kg, making the meeting with the FDA another key catalyst. It is possible regional deals could be struck prior to this readout given that potential partners may want to lock in a deal beforehand or risk having to pay more if the top line readout is a smashing success. PAR should have enough data to secure an upfront payment prior to the top line readout.
So the key catalyst will be the P3 OA top line readout,...
-
- There are more pages in this discussion • 184 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $76.95M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 23.5¢ | 22.0¢ | $66.95K | 294.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 90092 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 25858 | 1 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |